REQUEST A DEMO
Total
USD $0.00
Search more companies

Aptabio Therapeutics Inc. (South Korea)

Main Activities: Scientific Research and Development Services
Full name: Aptabio Therapeutics Inc. Profile Updated: July 04, 2023
Buy our report for this company USD 19.99 Most recent financial data: 2022 Available in: English Download a sample report

Aptabio Therapeutics Inc. is engaged in provision of pharmaceutical products. The company's products portfolio includes anticancer drugs and other pharmaceutical products. Aptabio Therapeutics Inc. was incorporated in 2009 and is based in Yongin, South Korea.

Headquarters
A-dong, 504-ho, 13, Heungdeok 1-ro Giheung-gu Yongin-si Gyeonggi
Yongin; Gyeonggi;

Contact Details: Purchase the Aptabio Therapeutics Inc. report to view the information.

Basic Information
Total Employees:
Purchase the Aptabio Therapeutics Inc. report to view the information.
Outstanding Shares:
Purchase the Aptabio Therapeutics Inc. report to view the information.
Registered Capital:
Purchase the Aptabio Therapeutics Inc. report to view the information.
Incorporation Date:
July 24, 2009
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Senior Managing Director
Ownership Details
Purchase this report to view the information.
27.7%
Purchase this report to view the information.
13.8%
Purchase this report to view the information.
7.3%
Company Performance
Financial values in the chart are available after Aptabio Therapeutics Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-78.38%
Total operating revenue
-78.38%
Operating profit (EBIT)
16.37%
EBITDA
18.15%
Net Profit (Loss) for the Period
1.16%
Total assets
-13.55%
Total equity
-15.07%
Operating Profit Margin (ROS)
-14579.3%
Net Profit Margin
-17070.4%
Return on Equity (ROE)
-2.84%
Debt to Equity Ratio
0.41%
Quick Ratio
-10.56%
Cash Ratio
-6.42%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?